GlassScriptPhysician profile
Jason Okuhara
NPI 1215158456
$1,236.21
in general payments reported to CMS, 2019-2025
18 companies · $399 in 2025
The $399 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $78.11 · 2021: $74.89 · 2022: $148 · 2023: $200 · 2024: $139 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $738.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $624.43 | 2020-2025 | Versacross Access Solution, Farapulse, Lux-Dx Insertable Cardiac Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.79 | 2019-2023 | Lifevest |
| Abbott Laboratories | $79.68 | 2022-2023 | Ensite Precision |
| Medtronic Vascular, INC. | $54.25 | 2019 | |
| Abiomed | $51.12 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $47.49 | 2022-2023 | Camzyos |
| Pfizer INC. | $46.55 | 2021-2024 | |
| Cardinal Health 200 LLC | $45.87 | 2019 | |
| Novartis Pharmaceuticals Corporation | $38.26 | 2023-2024 | |
| Medtronic, INC. | $26.15 | 2021-2022 | |
| Philips North America LLC | $20.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $18.84 | 2020 | |
| Janssen Pharmaceuticals, INC | $17.06 | 2023 | Xarelto |
| Terumo Medical Corporation | $16.35 | 2024 | Angio-Seal, Azur Cx Detachable |
| Braemar Manufacturing, LLC | $16.15 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $14.24 | 2019 | |
| Amgen INC. | $14.11 | 2023 | Repatha |
| Actelion Pharmaceuticals US, INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Okuhara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.